View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 12, 2020

Covid-19 vaccine development is picking up pace, supported by government and private funds

By Victoria Smith

The pace is picking up in the fight to develop a Covid-19 vaccine; more companies are beginning to form collaborations and begin clinical trials to ensure rapid development, as well as sufficient production capacity. There is optimism in the number of vaccine candidates and techniques in progress. However, the history of vaccine development highlights roadblocks and setbacks, which are almost guaranteed, indicating that a finished product will not likely be readily available this year.

Despite Gilead releasing positive (yet inconclusive) data from its antiviral remdesivir trial, a vaccine remains the ultimate goal to prevent future outbreaks of the deadly Covid-19. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena